Divi's Laboratories Limited vs Gujarat Kidney And Super Speciality Limited

A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Gujarat Kidney And Super Speciality Limited (GKSL) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divi's Laboratories Limited leads DIVISLAB vs GKSL on 10 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability31
  • Growth· not comparable—
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

DIVISLAB takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.52
P/E ratio
95.68
14.90
P/B ratio
5.41
0.32%
Dividend yield
0.00%
₹96.75
EPS
₹1.97

Profitability

DIVISLAB takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

15.32%
Return on equity
6.14%
20.35%
Return on capital
8.62%
32.59%
EBITDA margin
32.85%
24.32%
Net margin
20.50%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y) even
—
12.09%
Profit CAGR (3Y) even
—

Size & financial health

DIVISLAB takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.45L Cr
Market cap
₹1,478 Cr
₹10,560 Cr
Revenue
₹82 Cr
₹2,568 Cr
Net profit
₹17 Cr
0.00
Debt / equity
0.06
Divi's Laboratories Limited
  • + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
  • − ["Stock is trading at 14.48 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
Gujarat Kidney And Super Speciality Limited
  • + ["Company has delivered good profit growth of 191.4% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 34.1%", "Company is almost debt free.", "Company has delivered good sales growth of 136.9% CAGR over last 5 years"]
  • − ["Stock is trading at 5.85 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend"]
Divi's Laboratories Limited full analysis Gujarat Kidney And Super Speciality Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.